Pune, India -- (SBWire) -- 12/07/2018 --Market Research Future (MRFR) in its recently published study report asserts that the Global Intravenous (IV) Solution Market growing further will reach USD 11,511.2 Mn. by 2022, registering 7.69% CAGR from 2016 to 2022. Intravenous (IV) Solution also known as IV fluid or drip is administered intravenously in the treatments for dehydration from illness or excessive activity, treatment of infection using antibiotics, cancer treatment through chemotherapy drugs and management of pain using certain medications and others.
Leveraging to the modern age, people have adopted the heady & unhealthy lifestyles which mirrors the prevalence of damaged immune system and various disorders. Factors such as immense of stress, lack of good quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling the immunodeficiency disorders.
Request Sample copy at https://www.marketresearchfuture.com/sample_request/1235
All these factors commutatively prompt the demand for effective medical treatments. Resultantly, the global Intravenous (IV) Solution market is growing pervasively on the global platform.
Increasing R&D funding, rapidly developing healthcare infrastructure and increasing healthcare expenditures are some of the major driving forces supporting the market growth. Technological advancements transpired in the medical science, are fostering the market growth exponentially, bringing up novel treatment procedures, & medications.
Additional factors substantiating the market growth include growing population and geriatric populace worldwide. Improving economic conditions are providing impetus to the market growth, enabling access to the quality life & the improved healthcare. Seminal efforts & investments transpired in the development of IV solution, by the key market players are paying off well, driving the market growth.
The MRFR analysis is segmented into four key dynamics;
By Types: Total Parenteral Solution, and Peripheral Parenteral Solution among others.
By Nutritional Contents: Amino Acid Solution, Carbohydrates, Vitamins & Minerals, and Parenteral Lipid Emulsion among others.
By End-Users: Hospitals & Clinics, Ambulatory, and Homecare among others.
By Regions: North America, Europe, APAC and the Rest of the World.
Industry, Innovation & Related News:
September 04, 2018 – Baxter International Inc. (US), a global leader in clinical nutrition, including premix IV solutions announced the addition of OLIMEL 7.6%, to its olive oil-based parenteral nutrition portfolio.
Approved in Canada, OLIMEL 7.6% is a ready-to-use solution designed to meet the needs of high-stress patients by combining the highest protein with the lowest glucose formulation available in a standardized, triple-chamber bag.
Competitive Players:
Braun Melsungen AG
ICU Medical
Fresenius Kabi AG
Amanta Healthcare
Baxter
Terumo Medical Corporation
And Grifols S.A. among others.
Browse Complete 121 Pages Premium Research Report Enabled with 100+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/intravenous-solution-market-1235
Global Intravenous Solution Market – Competitive Analysis
The market is fiercely competitive with the presence of several large and small players active in the market. These market players acquire promising companies to expand in the fast-growing markets, focusing on improving their market performance. The market structure is dynamic due to the acquisition of local manufactures by the multinational companies. Strategies like product innovations and technologies are creating strong investment opportunities for the market players.
Intravenous Solution Market – Geographical Analysis
Globally, North America region is the leading market for Intravenous Solution, accounting for the largest revenue pocket, followed by the Europe & Asia Pacific markets, respectively. Attributing to the high IV consumption rate due to the high prevalence of chronic diseases is predominantly driving the market growth.
The US market backed by the high healthcare expenditure account for the largest contributor to the market growth in the region. Moreover, increasing prevalence of immunodeficiency disorder and rising demand for treatment measures provide impetus to the market growth.
Europe region stands as the second-largest market for intravenous solution, worldwide. The market is fostered by the high per capita income and robust proliferation of healthcare sector in the region. Growing markets in the countries like Germany & France drive the market growth in the region, at a large scale. Attributing to the increasing investment in health care and the rising number of patients with chronic diseases, the market is projected to witness a phenomenal CAGR during the forecast period.
Asia Pacific market for the intravenous solution is expected to perceive an exponential growth. Due to the huge population and the burgeoning medical treatment market, India & China drive the market growth in the region. Furthermore, owing to the emergence of high-quality and better healthcare infrastructure and institutions, the APAC Intravenous Solution Market is estimated to register a CAGR of 8.34% during the forecast period (2016 to 2022).
Check Discount at https://www.marketresearchfuture.com/check-discount/1235
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
Intravenous Solution Market Top Manufacturers, Detailed Segmentation, Competitive Landscape and Outlook Till 2022
Intravenous (IV) Solution Market Report Examines the Market position and viewpoint of the market globally, from various angles, such as key players, Geographical Analysis, Major Drivers, Share Revenue and Foreseen to 2022.